Results per Page:
Nuanced and far-reaching effects of gamma secretase inhibition in the multiple myeloma patients
From the Damian Green Lab, in collaboration with the Geoff Hill and Riddell Labs, Translational Sciences and Therapeutics Division and David Coffey, Division of Myeloma, at the University of Miami
When it comes to cancer trials, what’s the (end)point?
New endpoint in multiple myeloma could mean faster drug approvals. Are more endpoint tweaks on the way?
Una dosis de bortezomib por semana es suficiente para tratar el mieloma múltiple
Del Dr. Rahul Banerjee, División de Investigación Clínica
Once-weekly bortezomib is enough to treat multiple myeloma
From Dr. Rahul Banerjee, Clinical Research Division
‘What are the odds?’
Light chain amyloidosis patient participates in clinical trial that ends up helping her sister-in-law
Multiple myeloma research to be presented at American Society of Hematology annual meeting
Dr. Rahul Banerjee to share insights on reducing financial toxicity, time toxicity and side effects of treatment
Something new and something old synergize to limit multiple myeloma relapse
From the Hill Lab, Translational Science and Therapeutics Division
How blood cancer research might help organ transplant patients
Fred Hutch study suggests certain immune cells are source of antibodies that attack donated organs
Leader in apheresis and cellular therapy, Dr. Michael Linenberger, retires
As professor emeritus, this respected mentor will continue to contribute to the UW fellowship program
New approach could make bone marrow transplantation safer, stronger
Tests prevented relapse, limited GVHD in laboratory models of leukemia, multiple myeloma
Measure 170 times, cut once: high-throughput drug screening for multiple myeloma
From Dr. Pamela Becker and Dr. David Coffey, Clinical Research Division
Tip Sheet: Looking ahead to 2021, COVID-19 vaccines, improving health outcomes — and more
Summaries of recent Fred Hutch research findings and other news
Scientists predict progress against COVID-19, cancer in 2021
After a challenging and deadly 2020, some hopeful predictions for the new year